α-Glucosidase-IN-119
α-Glucosidase-IN-119 is an α-glucosidase inhibitor with an IC50 of 3.32 μM and oral effectiveness. α-Glucosidase-IN-119 acts as an antihyperglycemic agent, reduces blood glucose levels, restores normal levels of alkaline phosphatase, aspartate transaminase, alanine transaminase, urea, blood urea nitrogen, and total protein, and exhibits antioxidant activity. α-Glucosidase-IN-119 can be used for the research of type 2 diabetes mellitus.
For research use only. We do not sell to patients.
- Formula: C27H19N5O5S
- Molecular Weight:525.54
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
α‑glucosidase 3.32 μM (IC50) |
In Vitro
α-Glucosidase-IN-119 (Compound 10e) (1-250 μM; 10 min) potently inhibits α-glucosidase with an IC50 of 3.32 μM, and its activity is 21.05-fold higher than that of Acarbose (HY-B0089)[1].
α-Glucosidase-IN-119 (31.25-1000 μg/mL; 30 min) induces dose-dependent hemolysis of red blood cells, with hemolysis rates ranging from 1.34% to 11.54% within the tested concentration range[1].
α-Glucosidase-IN-119 (31.25-1000 μg/mL) exhibits moderate DPPH free radical scavenging activity, with an IC50 value of 105.68 μg/mL[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Wistar (male, 8-10 weeks old, 150-180 g, streptozotocin-induced type 2 diabetes)[1]
-
Dosage:10 mg/kg; 50 mg/kg
-
Administration:p.o.; 21 days
-
Result:Significantly reduced fasting blood glucose levels compared to the diabetic control group (p < 0.001) by day 14, with further improvement by day 21.
Significantly blunted post-prandial blood glucose rises and reduced the area under the glucose curve compared to the diabetic control group (p < 0.001).
Significantly reduced serum total cholesterol and triglyceride levels compared to the diabetic control group (p < 0.001).
Significantly reduced serum aspartate transaminase (AST) and alanine transaminase (ALT) levels, and restored total protein levels to near-normal compared to the diabetic control group (p < 0.001).
Significantly reduced blood urea nitrogen (BUN), serum creatinine, and serum urea levels compared to the diabetic control group (p < 0.001).
Restored hepatic architecture (reduced sinusoid dilation, inflammation), renal architecture (reduced glomerular constriction, tubular necrosis), and pancreatic islet structure (increased β-cell population, restored cell boundaries) compared to the diabetic control group.
Chemical Information
-
Molecular Weight 525.54
-
Formula C27H19N5O5S
-
SMILES
O=C(/C(S1)=C/C2=CN(C3=CC=CC=C3)N=C2C4=CC=CC([N+]([O-])=O)=C4)N(CC(NC5=CC=CC=C5)=O)C1=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Protein Extraction
Protein extraction uses physical, chemical or biological methods, such as ultrasonic disruption, salting out, cell lysis, electrophoresis, etc., to destroy the cell membrane structure and to separate the proteins from different components according to their characteristics.
-
Research Protocol for Metabolic Diseases
AMP-activated protein kinase, AMPK, is a conserved cellular energy sensor that responds to reduced cellular energy status and coordinates metabolism by increasing ATP-generating catabolic pathways while suppressing ATP-consuming anabolic processes. In metabolic disease research, the AMPK pathway is experimentally relevant because it regulates hepatic lipid synthesis, fatty acid oxidation, glucose production, skeletal-muscle glucose disposal, mTORC1-linked biosynthesis, autophagy, mitochondrial homeostasis, and whole-body energy balance. The central pathway logic is that energy stress, metformin, exercise-like stimulation, or direct AMPK activators increase AMPKα Thr172 phosphorylation and downstream substrate phosphorylation, including ACC and RAPTOR. Phosphorylation of ACC suppresses lipogenesis and supports fatty acid oxidation, whereas phosphorylation of RAPTOR suppresses mTORC1 signaling and links cellular energy status to growth and protein synthesis control. The pathway is linked
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)